Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1239060 10.3389/fphar.2023.1239060 Pharmacology Correction Corrigendum: Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer’s disease Luo et al. 10.3389/fphar.2023.1239060 Luo Yunxia 1 2 † Li Dongli 1 † Liao Yanfang 1 † Cai Chuipu 1 Wu Qihui 1 Ke Hanzhong 3 4 Liu Xinning 1 Li Huilin 2 Hong Honghai 5 Xu Yumin 6 Wang Qi 1 7 * Fang Jiansong 1 7 * Fang Shuhuan 1 7 * 1 Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China 2 Department of Endocrinology, Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China 3 Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States 4 Department of Medicine, Harvard Medical School, Boston, MA, United States 5 Department of Clinical Laboratory, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China 6 Department of Encephalopathy First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China 7 Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China

Edited and reviewed by: Wei Peng, Chengdu University of Traditional Chinese Medicine, China

 *Correspondence: Qi Wang, wangqi@gzucm.edu.cn; Jiansong Fang, fangjs@gzucm.edu.cn; Shuhuan Fang, fangshuhuan@gzucm.edu.cn

These authors have contributed equally to this work

 06 10 2023 2023 14 1239060 23 08 2023 22 09 2023 Copyright © 2023 Luo, Li, Liao, Cai, Wu, Ke, Liu, Li, Hong, Xu, Wang, Fang and Fang. 2023 Luo, Li, Liao, Cai, Wu, Ke, Liu, Li, Hong, Xu, Wang, Fang and Fang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer’s disease by Luo Y, Li D, Liao Y, Cai C, Wu Q, Ke H, Liu X, Li H, Hong H, Xu Y, Wang Q, Fang J and Fang S (2020). Front. Pharmacol. 11:381. doi: 10.3389/fphar.2020.00381 systems pharmacology Kai-Xin-San Alzheimer’s disease cholinergic system neuroinflammation section-at-acceptance Ethnopharmacology

In the published article, there was an error in Figure 8 as published. The Iba1 fluorescence image of the cortex and corresponding merged image in the KXS-L group was mistakenly displayed. The corrected Figure 8 and its caption appear below.

Kai-Xin-San (KXS) attenuates microglia activation in scopolamine (SCOP)-induced mice. Immunofluorescence analysis in the hippocampus (CA1) and cortex. Microglia were stained with anti-Iba-1 (red) and the nuclei were stained with DAPI (blue). Scale bar: 50 mm. Con, control group; SCOP, scopolamine; KXS-L, low-dose Kai-Xin San (1.4 g/kg); KSX-H, high-dose Kai-Xin San (2.8 g/kg); Don, donepezil.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.